SAB Biotherapeutics (SABS) Capital Expenditures (2021 - 2026)

SAB Biotherapeutics (SABS) posted Capital Expenditures of $255376.0 for Q1 2026, up 361.16% on a QoQ basis from $55377.0 in Q4 2024.

SAB Biotherapeutics (SABS) Capital Expenditures (2021 - 2026) Analysis & Trends

SAB Biotherapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $255376.0 for Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to $255376.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $463564.0 (changed N/A YoY) and the FY2025 annual result came in at $933156.0, up 176.69% from the prior year.
Capital Expenditures was $255376.0 for Q1 2026 at SAB Biotherapeutics, up from $55377.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $1.4 million in Q1 2022 and bottomed at $21300.0 in Q1 2023.
A 4-year average of $227400.5 and a median of $85306.0 in 2023 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2023 — Capital Expenditures plunged 98.43% — and 2024, when it jumped 505.98%.
SAB Biotherapeutics' Capital Expenditures stood at $117754.0 in 2022, then sank by 42.37% to $67864.0 in 2023, then retreated by 18.4% to $55377.0 in 2024, then jumped by 361.16% to $255376.0 in 2026.
Business Quant data shows SABS's Capital Expenditures at $255376.0 in Q1 2026, $55377.0 in Q4 2024, and $100300.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	SAB Biotherapeutics	170.64 Mn	170.64 Mn	-	255,376.00

Download Data